Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Camidanlumab tesirine |
| Synonyms | |
| Therapy Description |
Camidanlumab tesirine (ADCT-301) is a human monoclonal antibody against CD25 linked to pyrrolobenzodiazepine dimer toxin, which may specifically target CD25-positive tumor cells (Blood 2017 130(Suppl 1):1510, PMID: 32521310, PMID: 32912922). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Camidanlumab tesirine | ADCT-301|ADCT 301|ADCT301 | Camidanlumab tesirine (ADCT-301) is a human monoclonal antibody against CD25 linked to pyrrolobenzodiazepine dimer toxin, which may specifically target CD25-positive tumor cells (Blood 2017 130(Suppl 1):1510, PMID: 32521310, PMID: 32912922). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03621982 | Phase I | Camidanlumab tesirine | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Terminated | USA | GBR | BEL | 0 |
| NCT02432235 | Phase I | Camidanlumab tesirine | Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma | Completed | USA | GBR | 0 |
| NCT04639024 | Phase II | Camidanlumab tesirine | ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN | Terminated | USA | 0 |
| NCT04052997 | Phase II | Camidanlumab tesirine | Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma | Completed | USA | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BEL | 0 |
CKB BOOST